Business
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to
About this update from Theravance Biopharma, Inc.
[{"type":"text","content":"YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summerCompleted sale of TRELEGY ELLIPTA royalty interest to GSK for $225 millionTRELEGY year-to-date sales on track to trigger $50 million milestone in 2025Strong balance sheet with $339 million in cash and no debtDUBLIN, Aug. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (\"Theravance Biopharma\" or the \"Company\") (NASDAQ: TBPH) today reported financial and operational results for the second quarter of 2025.\n\n \n \n \n \n \n \n\n \n\"Strong execution across our business defined the second quarter, driven by commercial growth, disciplined operations, and continued progress on ampreloxetine. YUPELRI posted another strong quarter in the U.S., and its recent approval in China triggered a $7.5 million milestone payment. With the completion of the strategic monetization of our TRELEGY royalty interest, which brought in $225 million, these accomplishments have meaningfully strengthened our business,\" said Rick E Winningham, Chief Executive Officer of Theravance Biopharma. \"We enter the second half of 2025 with momentum and a clear focus on ampreloxetine. We remain on track for completing the enrollment in our pivotal Phase 3 CYPRESS study in late summer, and continue to prepare for reporting top-line data approximately six months later.\"\nSecond Quarter Operational Highlights:\nYUPELRI® (revefenacin) inhalation solution, the first and only once-daily, nebulized LAMA (long-acting muscarinic antagonist) bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD):\nAchieved total U.S. net sales of $66.3 million in Q2 2025, increasing 22% year-over-year (Q2 2025 vs Q2 2024).1Grew customer demand 4% for the quarter (Q2 2025 vs Q2 2024).2Net sales benefited from continued improvement to net pricing and a one-time favorable adjustment to net price. Excluding the one-time adjustment, year-over-year net sales growth would have been in the mid-teens.Increased doses pulled through the hospital channel by 31% year-over-year (Q2 2025 vs Q2 2024), reflecting another quarter of strong momentum.3Earned $7.5 million milestone payment from Viatris in Q2 2025 for YUPELRI approval in China.Ampreloxetine, an...